---
title: "Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ANIK Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288905969.md"
description: "Anika Therapeutics (NASDAQ: ANIK) announced inducement grants under Nasdaq Listing Rule 5635(c)(4). On June 1, 2026, the company granted restricted stock units (RSUs) for 3,360 shares to a newly hired non-executive employee as a material inducement for employment. The RSUs vest in three equal installments over three years, contingent on continuous service. This grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, which did not require stockholder approval."
datetime: "2026-06-05T13:00:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288905969.md)
  - [en](https://longbridge.com/en/news/288905969.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288905969.md)
generator: "portal-rs"
---

# Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ANIK Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on June 1, 2026, Anika granted restricted stock units (“RSUs”) covering an aggregate of 3,360 shares of common stock to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.

The RSUs will vest in three equal installments on each of the first three anniversaries of the grant date, in each case for so long as the grantee provides continuous service to Anika through the relevant vesting date.

The RSUs are subject to the terms and conditions of the equity award agreement approved by Anika. The RSUs were granted pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, which was not subject to stockholder approval.

**About Anika** 

Anika Therapeutics, Inc. (NASDAQ: ANIK), is the global leader in the design, development, manufacturing, and commercialization of hyaluronic acid innovations. In partnership with clinicians, our sole focus is dedicated to delivering and advancing osteoarthritis pain management and orthopedic regenerative solutions. At our core is a passion to deliver a differentiated portfolio that improves patient outcomes around the world. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.

**For Investor Inquiries:**  
Anika Therapeutics, Inc.  
Matt Hall, 781-457-9554  
Director, Corporate Development and Investor Relations  
investorrelations@anika.com

### Related Stocks

- [ANIK.US](https://longbridge.com/en/quote/ANIK.US.md)

## Related News & Research

- [Anika Reports First Quarter 2026 Financial Results | ANIK Stock News](https://longbridge.com/en/news/284554290.md)
- [Anika (ANIK) Q1 2026 Earnings Transcript](https://longbridge.com/en/news/284614979.md)
- [This Geothermal Stock Is Soaring Today After a Major Google Deal](https://longbridge.com/en/news/297694810.md)
- [Swampscott Municipal Integrated Pest Management Program Achieves 43% Reduction in Rodent Activity with Evolve® Rat | SNES Stock News](https://longbridge.com/en/news/297518378.md)
- [14:21 ETNew Poll Shows Ed Markey's Support Slipping in Deep Blue Massachusetts](https://longbridge.com/en/news/297947167.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**